retatrutide clinical trials phase Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal 3 obesity trial Retatrutide for weight loss: Study

Retatrutide remains investigational, with Phase 3 trials ongoing and potential approval not expected until mid-2026 or 2027 at the earliest

Review our note about shipping this product*

And if you are making treatment decisions based on that misunderstanding, you could be heading down a path that does not match your goals, your body, or your medical needs

Faghris comprehensive research portfolio encompasses the study of occupational health and safety, examining workplace stressors and their impact on chronic diseases such as mental health issues, cardiovascular conditions, obesity, and type 2 diabetes

Our results revealed that Y1-R agonism resulted in insulin-independent glucose uptake into muscle, but only in the presence of elevated glucose levels 74

doi: 10.1210/en.2007-1137 29 ShiraishiDFujiwaraYKomoharaYMizutaHTakeyaM